Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services

•    Created on the basis of an existing collaborative platform, Platine Pharma Services is owned equally by Innate Pharma and Transgene.
•    Platine’s ambition is to become a European leader in preclinical and clinical immunomonitoring.

Innate Pharma (Euronext Paris: FR0010331421) and Transgene (Euronext Paris: FR0005175080) –  two biotechnology companies specialized in the development of innovative immuno therapeutics, announce the creation of Platine Pharma Services (« Platine »). Platine is a new immunomonitoring  company providing fee-based services to the healthcare industry for the preclinical and clinical development of prophylactic and therapeutic drug candidates, notably those with immune modulation activity such as vaccines, monoclonal antibodies or cytokines. Platine is owned equally by Innate Pharma and Transgene.